Clinical Trial Update: A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis [Phase 1]

View source ↗

Summary

The Phase I study of intrathecal rituximab for lymphomatous meningitis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Lymphomatous Meningitis

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: International Extranodal Lymphoma Study Group (IELSG) | Conditions: Lymphoma, B Cell | Phase 1 | Status: WITHDRAWN